Tech Company Financing Transactions
Imbria Pharmaceuticals Funding Round
Imbria Pharmaceuticals closed a $57.5 million Series B financing round on 4/11/2025. Backers included Deep Track Capital, Catalio Capital Management and RA Capital Management.
Transaction Overview
Company Name
Announced On
4/11/2025
Transaction Type
Venture Equity
Amount
$57,500,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the proceeds to advance ninerafaxstat through a Phase 2b randomized, double-blind, placebo-controlled, clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM), called FORTITUDE-HCM, and to initiate FORTITUDE-HCM in Q2 2025, with topline data in late 2026.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
265 Franklin Street 1702
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Undisclosed
Website
Email Address
Overview
At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell's ability to produce energy in cardiovascular diseases where energetic impairment is a fundamental contributor.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alvin Shih
Browse more venture capital transactions:
Prev: 4/11/2025: APX Lending venture capital transaction
Next: 4/11/2025: Meanwhile venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs